Home Tags US FDA

Tag: US FDA

The Pullback in AbbVie May be a Strong Buy Opportunity

The pullback in AbbVie Inc. (ABBV) is overdone. Shortly after the US FDA mandated new heart safety and cancer warnings for the company’s immunology drug...

Vaccine Stocks: Another Pandemic Spike May be Ahead

The pandemic is getting out of hand. At the moment, about 160,000 Americans are testing positive for CV-19 every day – an increase of about...

Ocugen Will No Longer Pursue an EUA for Covaxin

Keep an eye on Ocugen (OCGN). The stock is pulling back after saying it would no longer pursue emergency use authorization (EUA) for its CV-19...

Alzheimer’s Disease: This Could be Game-Changing News

Keep an eye on Biogen (BIIB). Over the next few days, the US FDA will decide on approving its Alzheimer’s disease therapy. At the moment, things...

This is Why Gene Editing Stocks May Be Exploding

Gene editing stocks are skyrocketing. While it’s not clear why, it may be thanks in part to Ark Investment Management CEO Cathie Wood, who noted,...

US FDA Says Moderna Vaccine is “Highly Effective”

Moderna (MRNA) just got a positive shot in the arm. All after the U.S. FDA said its vaccine is safe and effective in people ages...

Moderna Could Run Higher Ahead of Dec. 17

We may be closer to a vaccine. Moderna (MRNA) just said new data shows its vaccine is 94% effective, and plans to seek US FDA...

The Pullback in Moderna May Only be Temporary

Investors may want to use weakness in Moderna (MRNA) as a buying opportunity. Just yesterday, the vaccine stock plummeted after Merck sold its stake in...

This is Why BioNTech is Still a Buy at $101

We’ve highlighted opportunity in BioNTech (BNTX) quite a few times. The first time was on May 5, as it traded at $48.50.  The most recent...

US FDA approves Gilead’s Remdesivir for the Treatment of Coronavirus

With the coronavirus still making its way around the world, the US FDA just approved Gilead Sciences’ antiviral drug remdesivir.  Reportedly, the drug has...

Popular Post